

What: Vaccine Committee Agenda  
Date & Time: March 7, 2024; 12:00-1:00 p.m. PT  
Location: Webinar/Teleconference

This meeting will take place solely by webinar. WVA values comments by the public about the work of the WVA. To register for the meeting, please review the [Public Comment Protocol](#) then email [wvameetings@wavaccine.org](mailto:wvameetings@wavaccine.org) at least two business days in advance of the meeting.

Notice: The meeting may be recorded for the benefit of the minute-taker. The WVA intends to delete the recording after the minutes are approved.

### Agenda

Approx. Time	Pg.		Topic/[Anticipated Action]	Presented by:
12:00-12:05 p.m.			1. Introductions/Notice of Recording	E. Marcuse
12:05-12:10 p.m.	Pg. 2-3 Pg. 4-5	* *	2. Action Items a. Approve Vaccine Committee Minutes (April 27, 2023) b. Approve Special Purpose Vaccine Committee Minutes (September 21, 2023)	E. Marcuse
12:10-12:30 p.m.			3. Nirsevimab Update a. Distribution & Uptake b. Provider Experience c. Health System Experience d. Legislation Status Update	DOH / A. Carter / J. Dunn / B.Harvey J. Dunn
12:30-12:35 p.m.			4. Respiratory Vaccine Distribution and Challenges a. Influenza Vaccines b. COVID-19 Vaccines	DOH / E. Marcuse
12:45-12:50 p.m.			5. Assessment of MMR Coverage by Geographic Area a. Risk of Outbreak	DOH / E. Marcuse
12:50-12:55 p.m.			6. WVA Updates a. Challenge of Providing Vaccine to Providers without Billing Systems: School-based Clinics, Local Health Jurisdictions	J. Zell
12:55-1:00 p.m.			7. Public Comment	Any
1:00 p.m.			8. Closing	E. Marcuse

\*Indicates agenda item attached  
Red text indicates an action item

1 **Meeting Notes**  
2 **Vaccine Committee Meeting**  
3 **April 27, 2023; 12:00-1:00 p.m. PT**  
4

5 **I. Attendance.** This meeting was conducted solely by webinar. Participating in all or part of the meeting  
6 were the following individuals:  
7

8 <u>Members</u>	21 <u>WVA</u>
9 Ed Marcuse, MD, Emeritus Professor of	22 Julia G. Zell, MA, Esq., Executive Director
10 Pediatrics, University of Washington, <i>Chair</i>	23
11 Pam Sheffield, MD, Aetna	24 <u>Helms &amp; Company, Inc.</u>
12 Amy Carter, MD, Allegro Pediatrics	25 Patrick Miller, MPH, WVA, Administrative
13 Helen Chea, MD, Molina Healthcare	26 Director
14 John Dunn, MD, Kaiser	27 Ashley Ithal, MPH, Project Support Leader
15 Jeff Gombosky, Pharmaceutical Research and	28
16 Manufacturers of America	29 <u>Other</u>
17 Janel Jorgenson, Washington Department of Health	30 Carrie Jenner, MD, Pierce County Immunization
18 Amy Person, MD, Benton-Franklin Health District	31 Coalition (PCIC)
19 Kristi A. Rice, MD, Providence	32 Breelyn Young, GSK
20 Sherri Zorn, MD, Independent Consultant	

33  
34 **II. Summary of Actions Taken and/or Recommended**  
35

36 Actions Taken (votes adopted)

- 37 i. To approve the November 16, 2022 Vaccine Committee meeting minutes with changes requested at the  
38 meeting.  
39

40 **III. Minutes**  
41

42 Welcome and Introductions

43 At 12:05 p.m. Dr. Marcuse called the meeting to order. Ms. Zell announced that the meeting would be recorded for  
44 the benefit of the minute taker, to be deleted once the minutes are approved.  
45

46 Calendar Consent Items

47 Dr. Marcuse asked for a motion to approve the minutes. Dr. Zorn asked for several clarifications. Upon motion duly  
48 made and seconded, it was unanimously

49 **VOTED: To approve the November 16, 2022 Vaccine Committee meeting minutes with changes**  
50 **requested at the meeting.**  
51

52 **IV. Department of Health (DOH) Updates**  
53

54 Staffing Updates

55 Ms. Jorgenson reported that the Department of Health (DOH) Office of Immunization is going through a COVID  
56 forward planning process to review all bodies of work and related positions connected to COVID now that the Public  
57 Health Emergency is ending and funding for those positions will end in 2024. It is expected that duties will either be  
58 incorporated into the Office of Immunization or transitioned to another part of the Department.  
59

60 Influenza Vaccine 2022-23; 2023-24

61 Ms. Jorgenson reported that influenza vaccine uptake was lower within the Childhood Vaccine Program (CVP) this  
62 season. Influenza vaccine distribution to date is at 67% of those doses purchased within the CVP. Historically, the  
63 distribution rates have been closer to 80%. Ms. Jorgenson reported that this year's influenza pre-book in February  
64 2023 was reduced by 30,000 doses based on provider ordering history. Dr. Zorn stated that many providers are hesitant  
65 to provide the FluMist vaccines due to concerns about lower efficacy.  
66  
67

68 Promoting HPV Vaccine at Age 9

69 Ms. Jorgenson reported that the DOH has incorporated the recommendation from the Vaccine Advisory Committee  
70 to encourage and promote the HPV vaccine series starting at age nine. The DOH has sent letters to providers  
71 specifically encouraging this. Dr. Zorn added that the DOH has provided a useful suite of materials for promoting  
72 HPV at age nine, including translation of these materials into various languages to reach a broader range of the  
73 population. Additionally, two HPV provider training webinars have been scheduled. Dr. Zorn reported that current  
74 coverage rates are climbing in the 9- to 10-year-old age group.

75  
76 Pneumococcal Vaccine Update (Prevnar 13, 20; Vaxneuvance)

77 Ms. Jorgenson provided an update on the potential licensure and ACIP consideration of Pfizer's Prevnar 20 (PCV20)  
78 vaccine for children. She provided the expected timeline for approval and other details about its potential to receive a  
79 ACIP recommendation. The PCV20 vaccine, if approved, is planned to replace the current product, however, both  
80 products will be available through the CVP through the CDC contract for a period of time. Ms. Jorgenson next provided  
81 an update on vaccine choice, and the window opened April 26 for two weeks to allow providers the option to change  
82 their vaccine brand, if desired. Discussion ensued within the Committee.

83

84 **V. Committee Discussions**

85

86 Status of Immunization Coverage Catch-up

87 Dr. Jenner reported improvement in well check-up visits including children that have not been seen since the start of  
88 the pandemic, and this is consistent with the quality improvement metrics being gathered in her clinics. Dr. Rice  
89 reported that she has not seen as many people coming to her clinics compared to rates pre-pandemic. Further, she  
90 reported that her clinics have seen a decline in meningitis vaccine administration at 11 years of age. Dr. Rice believes  
91 vaccine hesitancy has increased and the reasons behind the hesitancy has changed. Dr. Dunn reinforced Dr. Rice's  
92 reporting and stated that immunization rates have not rebounded as expected. The Committee concurred that slow  
93 coverage catch-up rates could be attributed to hesitancy or difficulty accessing provider offices.

94

95 COVID Vaccines

96 Dr. Carter expressed concerns about the unknowns around COVID commercialization information. Dr. Dunn stated  
97 that the messaging is difficult to create that would convince vaccine-hesitant people to seek a COVID vaccine for  
98 themselves or their children.

99

100 Prospects for RSV Vaccine

101 Dr. Marcuse and Dr. Dunn discussed the complexity of the RSV vaccines in the current pipeline. Related, Dr. Dunn  
102 shared a recent article from the New England Journal of Medicine which discusses the design of these vaccines  
103 (available at: <https://www.nejm.org/doi/full/10.1056/NEJMp2216358>). Dr. Carter also shared a recent article from  
104 Scientific American about the importance of RSV vaccine development (available at:  
105 <https://www.scientificamerican.com/article/rsv-vaccines-are-nearly-here-after-decades-of-false-starts/>). Dr. Marcuse  
106 expects that two RSV vaccines are on the horizon that the WVA will need to consider.

107

108 Guidance for Distribution of Educational Opportunities

109 Dr. Marcuse discussed a process for continuing education opportunities through this group via communications from  
110 Ms. Zell. Discussion regarding distribution of opportunities for continuing vaccine education occurred.

111

112 **VI. Public Comments**

113

114 No public comments.

115 **VII. Closing**

116

117 The meeting adjourned at 12:59 p.m. PT.

**Meeting Notes**  
**Special RSV Vaccine Committee Meeting**  
**September 21, 2023; 7:00-8:00 a.m. PT**

- I. Attendance.** This meeting was conducted solely by webinar. Participating in all or part of the meeting were the following individuals:

Members

Ed Marcuse, MD, Emeritus Professor of Pediatrics, University of Washington, Chair	Julia G. Zell, MA, Esq., WVA Executive Director
Amy Carter, MD, Allegro Pediatrics	Cheri Cagle, WVA Stakeholder Liaison
John Dunn, MD, Kaiser Permanente	
Jeff Gombosky, PhD, Pharmaceutical Research and Manufacturers of America	<u>Helms &amp; Company, Inc.</u>
Rick Hourigan, MHA, MD, Cigna	Patrick Miller, MPH, WVA Administrative Director
Carrie Jenner, MD, Pierce County Immunization Coalition	Ashley Ithal, MPH, WVA Project Support Leader
Janel Jorgenson, Washington Department of Health	Leslie Walker, CPA, Mason+Rich
Chad Murphy, RPh, Premera	
Amy Person, MD, Benton-Franklin Health District	<u>Other</u>
Kristi A. Rice, MD, Providence	Helen Chea, MD, Molina Healthcare
Michele Roberts, Washington Department of Health	Beth Harvey, MD, South Sound Pediatrics
Hailey Sly, Washington Department of Health	Pam Sheffield, MD, Aetna
Sherri Zorn, MD, Independent Consultant	Kiran Griffith, Esq., Stohl Rives, LLP
	Frank Bell, MD, Swedish
	Juliet Dang, PhD, Sequirus
	Nicholas Fisher, Sanofi
	Neil Kaneshiro, Premera
	Breelyn Young, GSK

WVA

**II. Summary of Actions Taken and/or Recommended**

The Vaccine Committee voted to adopt the following recommendations to be presented to the Board of Directors:

1. WVA to work with DOH to make nirsevimab monoclonal antibody part of WA State Universal Vaccine Purchase Program.
2. WVA to develop a funding mechanism to protect against liability pending modification of statute governing WVA.
3. WVA to collaborate with DOH, WCAAP, and others to modify statute this legislative session to update definition of "Vaccine".

**III. Minutes**

Welcome and Introductions

At 7:02 a.m. Dr. Marcuse called the meeting to order. Ms. Zell announced that the meeting would be recorded for the benefit of the minute taker, to be deleted once the minutes are approved.

Dr. Marcuse provided an overview of nirsevimab, which was recommended by the Advisory Committee on Immunization Practices (ACIP) for inclusion on the CDC's immunization schedule and the Vaccines for Children (VFC) program. Dr. Marcuse confirmed that the purpose of today's meeting is for the Vaccine Committee to develop consensus on recommendation(s) that will be presented to the Board of Directors at their next meeting.

WCAAP Presentations

Dr. Marcuse discussed the importance to obtain consultation from third-party, non-board member experts to inform the Committee's deliberations and recommendations on this matter. The following individuals provided their perspectives to the Committee:

- Dr. Frank Bell, Swedish, a pediatric infection disease specialist based in the Tacoma.
- Dr. Amy Carter, Chief Medical Officer and Pediatrician, Allegro Pediatrics.
- Janel Jorgenson, Vaccine Management Section Manager, WA Department of Health (DOH).

75 Dr. Marcuse asked for additional perspectives from these individuals be provided to the Committee:

- 76     • Ms. Zell, Executive Director, Washinton Vaccine Association.  
77     • Kiran Griffith, Esq., Stohl Rives, LLP.

78  
79 Dr. Marcuse invited discussion which ensued.

80  
81 Upon motion duly made and seconded, it was unanimously:

82  
83         **VOTED: To approve and recommend the following recommendations to the Board regarding**  
84         **nirsevimab:**

- 85  
86         1. **WVA to work with DOH to make nirsevimab monoclonal antibody part of WA State Universal Vaccine**  
87         **Purchase Program.**  
88         2. **WVA to develop a funding mechanism to protect against liability pending modification of statute**  
89         **governing WVA.**  
90         3. **WVA to collaborate with DOH, WCAAP, and others to modify statute this legislative session to update**  
91         **definition of “Vaccine”.**

92  
93  
94         **IV. Public Comments**

95  
96 No public comments.

97         **V. Closing**

98  
99 The meeting adjourned at 7:57 a.m. PT.